Lung cancer has long been framed as a disease of smoking, and tobacco remains the dominant driver of cases worldwide. But as smoking and smoking-related cancers decline in many regions, a different concern is moving into focus: the people who develop lung cancer despite never having smoked. A research highlight published in Nature Medicine on 28 September 2026 examines one of the most intriguing threads in that story — rare inherited variants of the EGFR gene, and specifically the germline mutation known as EGFR T790M.
Written by Karen O’Leary, an associate research analysis editor with Nature Medicine, the highlight summarizes a study that drew on data from more than 3 million people. The aim was twofold: to trace the ancestral history of the EGFR T790M germline mutation, and to pin down its present contribution to lung cancer risk among individuals who have never smoked.
The variant at the center of the story
EGFR — the epidermal growth factor receptor gene — has been a fixture of lung cancer research for years, largely because of its role in tumor biology and targeted therapy. The T790M change occupies a particular place in that landscape. It is a rare germline variant, meaning it can be inherited and carried in every cell of the body rather than arising only inside a tumor.
That distinction matters. Germline variants can be passed down through families, which is why EGFR T790M has been repeatedly linked to familial lung cancers. When the same variant appears across multiple generations of a family with an unusual concentration of lung cancer, the question of inheritance becomes difficult to dismiss as coincidence.
Why the never-smoker population is central
In people who have smoked, the carcinogenic burden of tobacco can overwhelm more subtle genetic contributions, making it hard to isolate the effect of any single inherited variant. In never-smokers, that background noise is much lower, so inherited risk factors can stand out more clearly. As the highlight notes, concern over the prevalence of lung cancer in never-smokers is growing — and rare germline EGFR variants sit near the center of that concern.
A question that earlier studies could not settle
EGFR T790M is not a new discovery. It has been implicated in familial lung cancer for some time. The problem was not the direction of the evidence but its weight: prior studies were small and lacked the statistical power needed to produce firm answers.
Statistical power is a persistent constraint in rare-variant genetics. When a variant occurs at very low frequency in the population, even a well-designed study may enroll too few carriers to distinguish a genuine risk signal from random variation. Small cohorts can hint at an association, but they struggle to quantify it, and they offer little leverage for reconstructing when and where a mutation first appeared.
That limitation explains why a variant can remain scientifically unresolved for years despite recurrent attention. The biology invites study; the numbers needed to study it well are hard to assemble.
Scaling the analysis to millions of people
The new work addresses that gap directly by working at population scale, drawing on data from over 3 million individuals. That order of magnitude changes what kinds of questions become tractable.
- Frequency estimates: large cohorts allow researchers to characterize how often a rare germline variant appears in the broader population, not just in families already flagged for cancer clustering.
- Risk quantification: with more carriers identified, the association between the variant and lung cancer in never-smokers can be measured with greater precision.
- Ancestral reconstruction: variant data spanning many populations provides the raw material for tracing a mutation’s deeper history and its spread across lineages.
- Confounder control: a large dataset supports comparisons that help separate inherited risk from other factors that shape cancer incidence.
In essence, the study treats an inherited risk variant less as a clinical curiosity and more as a measurable population phenomenon with a traceable biography.
Tracing ancestry, estimating present-day risk
The two halves of the analysis reinforce each other. Reconstructing the ancestral history of EGFR T790M places the variant in time and in the context of human migration and population structure. Measuring its current contribution to lung cancer risk among never-smokers connects that history to contemporary clinical reality.
For researchers, the pairing offers a way to move past a binary question — is this variant harmful or not? — toward something more nuanced. A variant’s history can inform expectations about who might carry it and how frequently it should appear in different populations. Its measured risk contribution, meanwhile, bears on how seriously a carrier result should be taken in a clinical setting.
A note on access
The full details of the findings, including the specific ancestral conclusions and the calculated risk estimates, sit behind the journal’s subscription options. The research highlight itself is an editorial summary of the work rather than a full methods-and-results treatment.
What the findings could mean downstream
If inherited EGFR variants are confirmed to carry meaningful risk in never-smokers, several areas of oncology and public health could feel the effects.
- Genetic counseling: families with apparent clustering of lung cancer may gain a more concrete variant to test for and a clearer basis for discussion.
- Screening strategy: current lung cancer screening programs lean heavily on smoking history as the eligibility criterion, which by design excludes never-smokers. Identifying inherited risk markers could eventually inform who else should be considered.
- Biology of never-smoker lung cancer: understanding why these tumors arise in the absence of tobacco exposure is a prerequisite for better prevention and treatment.
- Drug development: EGFR is already a well-established therapeutic target, and clarifying the inherited dimension adds context to how these tumors behave.
Open questions that remain
Large datasets resolve some uncertainties and sharpen others. Among the questions that persist:
- How should a rare germline variant’s risk be communicated when absolute risk for any individual carrier may still be modest?
- How do EGFR T790M and other inherited variants interact with environmental exposures, including secondhand smoke, air pollution, and occupational hazards?
- Should population-scale carrier data translate into routine testing, and for whom?
- How do findings derived from millions of genomes perform in smaller, more diverse clinical settings?
The broader context
The highlight appears alongside related Nature Medicine coverage on cancer detection and risk, including work on multi-cancer early detection testing and long-term health risks following smoking cessation with e-cigarette use. Taken together, the journal’s recent output reflects a field increasingly organized around early identification and stratified risk rather than a single, uniform definition of who is at risk.
For never-smokers with lung cancer, that shift matters. A population that was once largely invisible in screening guidelines and awareness campaigns is becoming the subject of focused genetic inquiry — and the biography of one inherited variant is part of how that story is being written.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
